The importance of adequate levels of muscle size and function and physical activity is widely
recognized. Myostatin/activin blocking increases skeletal muscle mass but may decrease …

Increasing the size and strength of muscles represents a promising therapeutic strategy for
musculoskeletal disorders, and interest has focused on myostatin, a negative regulator of …

Background The treatments currently approved for Duchenne muscular dystrophy (DMD), a
progressive skeletal muscle wasting disease, address the needs of only a small proportion …

Many growth factors are intimately bound to the extracellular matrix, with regulated
processing and release leading to cellular stimulation. Myostatin and GDF11 are closely …

Suppression of the myostatin (GDF‐8) pathway has emerged as an important therapeutic
paradigm for muscle‐wasting disorders. In this study, we conducted a translational …

Insulin resistance (IR) in skeletal muscle is a prerequisite for type 2 diabetes and is often
associated with obesity. IR also develops alongside muscle atrophy in older individuals in …

A decade has passed since myostatin was first identified as a negative regulator of muscle
growth. Since then, studies in both humans and animals have demonstrated that decreasing …

Myostatin (MSTN) is a secreted signaling molecule that normally acts to limit muscle mass.
In adult animals, MSTN is made almost exclusively by skeletal muscle and circulates in the …

Myostatin is a negative regulator of skeletal muscle growth. Myostatin mutations and
pharmacological strategies increase muscle mass in vivo, suggesting that myostatin …

Background Myostatin inhibition is a promising therapeutic strategy to maintain muscle mass
in a variety of disorders, including the muscular dystrophies, cachexia, and sarcopenia …